Serum matrix metalloproteinase-3 levels monitor the therapeutic efficacy in Syrian patients with rheumatoid arthritis
Background: The plans for the successful treatment of rheumatoid arthritis (RA) seek to attain low disease activity or reach clinical remission. Objective: Our study aimed to compare the serum MMP-3 levels with predictors of response to therapy of rheumatoid arthritis in Syrian patients and explore...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-03-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S240584402301215X |
| _version_ | 1797851842272559104 |
|---|---|
| author | Rama Hussein Imad Aboukhamis |
| author_facet | Rama Hussein Imad Aboukhamis |
| author_sort | Rama Hussein |
| collection | DOAJ |
| description | Background: The plans for the successful treatment of rheumatoid arthritis (RA) seek to attain low disease activity or reach clinical remission. Objective: Our study aimed to compare the serum MMP-3 levels with predictors of response to therapy of rheumatoid arthritis in Syrian patients and explore its worth as a new valuable biomarker for RA therapy outcomes in daily practice. Methods: Serum samples were gathered from 43 RA patients at diagnosis and 12 weeks of therapy. Related clinical and laboratory tests were estimated, levels of serum MMP-3 were measured by ELISA method and the disease activity was assessed using disease activity scores in 28 joints with an erythrocyte sedimentation rate (DAS28-ESR) before and after therapy. Results: The mean of Serum MMP-3 levels significantly decreased (322.3 ± 43.83 ng/ml) after therapy (12 weeks) in RA patients compared to its mean at baseline (486.49 ± 34.5 ng/ml). There wasn't a statistically significant difference in the mean of MMP-3 levels before and after therapy (P = 0.137) in non-responder patients. Patients who showed a good response (N = 38) presented higher MMP-3 levels at first which subsequently decreased significantly at the 12-week follow-up (P < 0.05). Also, there was a statistically significant difference in MMP-3 levels between the two groups of patients after therapy (P = 0.002). To differentiate between RA patients who responded to therapy and who did not, our results found that the cut-off value of serum MMP-3 was 317.8 ng/ml (sensitivity was 80%, specificity was 73%, AUC was 0.818, 95% CI: 1.114–112.5; P = 0.045) and the best cut-off value of DAS28-ESR was 5.325 (sensitivity 100%, specificity 100%, AUC = 100%,95% CI: 15.2 to 47203.8). Conclusion: serum MMP-3 can be added as a novel and valuable biomarker in estimating the therapeutic response in RA patients, but it isn't better than DAS28-ESR. |
| first_indexed | 2024-04-09T19:24:20Z |
| format | Article |
| id | doaj.art-48cd4f1e06324331a6793339a6335f08 |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-04-09T19:24:20Z |
| publishDate | 2023-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-48cd4f1e06324331a6793339a6335f082023-04-05T08:20:19ZengElsevierHeliyon2405-84402023-03-0193e14008Serum matrix metalloproteinase-3 levels monitor the therapeutic efficacy in Syrian patients with rheumatoid arthritisRama Hussein0Imad Aboukhamis1Corresponding author.; Department of Hematology and Immunology, Faculty of Pharmacy, Damascus University, SyriaDepartment of Hematology and Immunology, Faculty of Pharmacy, Damascus University, SyriaBackground: The plans for the successful treatment of rheumatoid arthritis (RA) seek to attain low disease activity or reach clinical remission. Objective: Our study aimed to compare the serum MMP-3 levels with predictors of response to therapy of rheumatoid arthritis in Syrian patients and explore its worth as a new valuable biomarker for RA therapy outcomes in daily practice. Methods: Serum samples were gathered from 43 RA patients at diagnosis and 12 weeks of therapy. Related clinical and laboratory tests were estimated, levels of serum MMP-3 were measured by ELISA method and the disease activity was assessed using disease activity scores in 28 joints with an erythrocyte sedimentation rate (DAS28-ESR) before and after therapy. Results: The mean of Serum MMP-3 levels significantly decreased (322.3 ± 43.83 ng/ml) after therapy (12 weeks) in RA patients compared to its mean at baseline (486.49 ± 34.5 ng/ml). There wasn't a statistically significant difference in the mean of MMP-3 levels before and after therapy (P = 0.137) in non-responder patients. Patients who showed a good response (N = 38) presented higher MMP-3 levels at first which subsequently decreased significantly at the 12-week follow-up (P < 0.05). Also, there was a statistically significant difference in MMP-3 levels between the two groups of patients after therapy (P = 0.002). To differentiate between RA patients who responded to therapy and who did not, our results found that the cut-off value of serum MMP-3 was 317.8 ng/ml (sensitivity was 80%, specificity was 73%, AUC was 0.818, 95% CI: 1.114–112.5; P = 0.045) and the best cut-off value of DAS28-ESR was 5.325 (sensitivity 100%, specificity 100%, AUC = 100%,95% CI: 15.2 to 47203.8). Conclusion: serum MMP-3 can be added as a novel and valuable biomarker in estimating the therapeutic response in RA patients, but it isn't better than DAS28-ESR.http://www.sciencedirect.com/science/article/pii/S240584402301215XRheumatoid arthritisMMP-3Therapeutic responseDAS28-ESR |
| spellingShingle | Rama Hussein Imad Aboukhamis Serum matrix metalloproteinase-3 levels monitor the therapeutic efficacy in Syrian patients with rheumatoid arthritis Heliyon Rheumatoid arthritis MMP-3 Therapeutic response DAS28-ESR |
| title | Serum matrix metalloproteinase-3 levels monitor the therapeutic efficacy in Syrian patients with rheumatoid arthritis |
| title_full | Serum matrix metalloproteinase-3 levels monitor the therapeutic efficacy in Syrian patients with rheumatoid arthritis |
| title_fullStr | Serum matrix metalloproteinase-3 levels monitor the therapeutic efficacy in Syrian patients with rheumatoid arthritis |
| title_full_unstemmed | Serum matrix metalloproteinase-3 levels monitor the therapeutic efficacy in Syrian patients with rheumatoid arthritis |
| title_short | Serum matrix metalloproteinase-3 levels monitor the therapeutic efficacy in Syrian patients with rheumatoid arthritis |
| title_sort | serum matrix metalloproteinase 3 levels monitor the therapeutic efficacy in syrian patients with rheumatoid arthritis |
| topic | Rheumatoid arthritis MMP-3 Therapeutic response DAS28-ESR |
| url | http://www.sciencedirect.com/science/article/pii/S240584402301215X |
| work_keys_str_mv | AT ramahussein serummatrixmetalloproteinase3levelsmonitorthetherapeuticefficacyinsyrianpatientswithrheumatoidarthritis AT imadaboukhamis serummatrixmetalloproteinase3levelsmonitorthetherapeuticefficacyinsyrianpatientswithrheumatoidarthritis |